Journals / Acta Medica Nicomedia / 2026 / Cilt: 9

BEYOND COLONIZATION: RISK STRATIFICATION FOR VANCOMYCIN-RESISTANT ENTEROCOCCI INFECTIONS IN CRITICALLY ILL PATIENTS

KOLONİZASYONUN ÖTESİNDE: KRİTİK HASTALARDA VANKOMİSİNE DİRENÇLİ ENTEROKOK ENFEKSİYONLARI İÇİN RİSK SINIFLANDIRMASI

Mehmet Erinmez(GAZİANTEP ÜNİVERSİTESİ, TIP FAKÜLTESİ)0000-0002-3570-3510
Şerife İnce(GAZİANTEP ÜNİVERSİTESİ, TIP FAKÜLTESİ)0009-0001-4983-9304
Zelal Çetinkaya(GAZİANTEP ÜNİVERSİTESİ, TIP FAKÜLTESİ)0009-0001-6680-1535
Ali Muhittin Taşdoğan(GAZİANTEP ÜNİVERSİTESİ, TIP FAKÜLTESİ)0000-0002-4017-9071
Pages
1–7
Publication Date
2026-10-29
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Factors associated with infection and the role of routine rectal VRE screening in patient follow-up warrant further study.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: To determine the frequency of VRE infection within 30 days after rectal colonization detected in the intensive care unit (ICU), and identify associated factors.
📊
Key Findings & Data:Methods: This retrospective cohort study included patients aged ≥17 years with VRE in ICU rectal screening cultures during 2016–2025.
💡
Conclusion & Impact:Factors associated with infection and the role of routine rectal VRE screening in patient follow-up warrant further study.
🔬Design:Modeling & Simulation
📍Scope:2016–2025 Verileri
⚙️Variables:vankomisine dirençli enterokok · kolonizasyon · rektal tarama

Abstract

Objective: To determine the frequency of VRE infection within 30 days after rectal colonization detected in the intensive care unit (ICU), and identify associated factors. Methods: This retrospective cohort study included patients aged ≥17 years with VRE in ICU rectal screening cultures during 2016–2025. The primary outcome was VRE infection within 30 days of the index culture, supported by VRE growth from a clinical specimen, compatible clinical findings, and a treatment decision, including infections diagnosed during subsequent hospital follow-up. Associated factors were evaluated using multivariable logistic regression. Results: Of 2,648 unique ICU patients, 1,887 (71.3%) underwent rectal screening; VRE was detected in 400, and 396 met the age criterion. Within 30 days, culture-confirmed VRE infection occurred in 58/396 (14.6%) and bloodstream infection in 27/396 (6.8%). Median time to infection was 4 days (IQR, 1–10). In the full-cohort model, age (adjusted odds ratio [aOR] per 10 years, 1.19; 95% CI, 1.00–1.41), prior carbapenem use (aOR, 2.23; 95% CI, 1.18–4.21), and each 1 g/dL lower hemoglobin (aOR, 1.22; 95% CI, 1.03–1.45) were associated with infection. In the SOFA-augmented model, lower hemoglobin (aOR, 1.26) and SOFA score (aOR per point, 1.13) were also associated. Conclusion: Culture-confirmed VRE infection occurred within 30 days in 14.6% of colonized ICU patients. These observational findings do not justify treating colonization itself; however, subsequent VRE infection is not negligible in critically ill patients. Factors associated with infection and the role of routine rectal VRE screening in patient follow-up warrant further study.

Özet

Amaç: Yoğun bakım ünitesinde (YBÜ) saptanan rektal vankomisine dirençli enterokok (VRE) kolonizasyonunu izleyen kültürle ve klinik olarak doğrulanmış VRE enfeksiyonlarının sıklığını ve ilişkili faktörleri değerlendirmek. Yöntem: Bu retrospektif kohort çalışmasına, 2016–2025 yılları arasında YBÜ’de alınan rektal tarama kültüründe VRE saptanan ≥17 yaş hastalar dahil edildi. Birincil sonlanım, indeks kültürden sonraki 30 gün içinde gelişen VRE enfeksiyonuydu. Enfeksiyon; klinik örnekte VRE üremesi, uyumlu klinik bulgular ve tedavi kararıyla doğrulandı. YBÜ sonrası hastane izleminde tanı alan enfeksiyonlar da dahil edildi. İlişkili faktörler çok değişkenli lojistik regresyonla değerlendirildi. Bulgular: Toplam 2.648 tekil YBÜ hastasının 1.887’sinde (%71,3) rektal sürüntü taraması uygulanmıştı; bunların 400’ünde VRE saptandı ve ≥17 yaş ölçütünü karşılayan 396 hasta analiz edildi. VRE kolonizasyonu sonrası ilk 30 günde 58/396 hastada (%14,6) kültürle doğrulanmış VRE enfeksiyonu, 27/396 hastada (%6,8) VRE kan dolaşımı enfeksiyonu saptandı. VRE enfeksiyonu gelişimine kadar medyan süre 4 gündü (ÇAA: 1–10). Tüm kohort modelinde yaş (10 yıl başına aOR: 1,19; %95 GA: 1,00–1,41), önceki karbapenem kullanımı (aOR: 2,23; %95 GA: 1,18–4,21) ve hemoglobinde her 1 g/dL düşüş (aOR: 1,22; %95 GA: 1,03–1,45) VRE enfeksiyonuyla ilişkiliydi. SOFA eklenen modelde hemoglobinde her 1 g/dL düşüş (aOR: 1,26) ve SOFA (puan başına aOR: 1,13) enfeksiyon gelişimi ile ilişkiliydi. Sonuç: YBÜ’de rektal VRE kolonizasyonu saptanan hastaların %14,6'sında 30 gün içinde kültürle doğrulanmış VRE enfeksiyonu gelişti. Bu gözlemsel bulgular kolonizasyonun tedavisini desteklemez. Ancak kritik hastalarda kolonizasyon sonrası enfeksiyon riski azımsanmamalıdır. Enfeksiyona özgü risk faktörlerinin ve rutin rektal taramanın hasta izlemindeki yerinin ileri çalışmalarla değerlendirilmesi gerekir.

🔖

Cite This Article

Erinmez, M., İnce, Ş., Çetinkaya, Z., Taşdoğan, A. M. (2026). BEYOND COLONIZATION: RISK STRATIFICATION FOR VANCOMYCIN-RESISTANT ENTEROCOCCI INFECTIONS IN CRITICALLY ILL PATIENTS. Acta Medica Nicomedia, Cilt: 9, 1–7. https://doi.org/10.53446/actamednicomedia.1997435

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (28)

  1. Butler-Laporte G, Cheng MP, McDonald EG, Lee TC. Using VRE screening tests to predict vancomycin resistance in enterococcal bacteremia. Infect Control Hosp Epidemiol. 2020;41(4):425-429. doi:10.1017/ice.2019.380
  2. Reynolds JL, Trudeau RE, Seville MT, Chan L. Impact of a vancomycin-resistant Enterococcus screening result on appropriateness of antibiotic therapy. Antimicrob Steward Healthc Epidemiol. 2021;1(1):e41. doi:10.1017/ash.2021.215
  3. Johnstone J, Chen C, Rosella L, et al. Patient- and hospital-level predictors of vancomycin-resistant Enterococcus bacteremia in Ontario, Canada. Am J Infect Control. 2018;46(11):1266-1271. doi:10.1016/j.ajic.2018.05.003
  4. O'Driscoll T, Crank CW. Vancomycin-resistant enterococcal infections: epidemiology, clinical manifestations, and optimal management. Infect Drug Resist. 2015;8:217-230. doi:10.2147/IDR.S54125
  5. Mac S, Fitzpatrick T, Johnstone J, Sander B. Vancomycin-resistant enterococci screening and isolation in the general medicine ward: a cost-effectiveness analysis. Antimicrob Resist Infect Control. 2019;8:168. doi:10.1186/s13756-019-0628-x
  6. French G. Safety and tolerability of linezolid. J Antimicrob Chemother. 2003;51 Suppl 2:ii45-ii53. doi:10.1093/jac/dkg253
  7. Vehreschild MJGT, Haverkamp M, Biehl LM, Lemmen S, Fätkenheuer G. Vancomycin-resistant enterococci: a reason to isolate? Infection. 2019;47(1):7-11. doi:10.1007/s15010-018-1202-9
  8. MacDougall C, Johnstone J, Prematunge C, et al. Economic evaluation of vancomycin-resistant enterococci control practices: a systematic review. J Hosp Infect. 2020;105(1):53-63. doi:10.1016/j.jhin.2019.12.007
  9. Johnstone J, Shing E, Saedi A, et al. Discontinuing contact precautions for vancomycin-resistant Enterococcus (VRE) is associated with rising VRE bloodstream infection rates in Ontario hospitals, 2009–2018: a quasi-experimental study. Clin Infect Dis. 2020;71(7):1756-1759. doi:10.1093/cid/ciaa009.
  10. Almyroudis NG, Osawa R, Samonis G, Wetzler M, Wang ES, McCarthy PL, Segal BH. Discontinuation of systematic surveillance and contact precautions for vancomycin-resistant Enterococcus (VRE) and its impact on the incidence of VRE faecium bacteremia in patients with hematologic malignancies. Infect Control Hosp Epidemiol. 2016;37(4):398-403. doi:10.1017/ice.2015.310.
  11. The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 16.1, 2026. https://www.eucast.org.
  12. Murray BE. Vancomycin-resistant enterococcal infections. N Engl J Med. 2000;342(10):710-721. doi:10.1056/NEJM200003093421007.
  13. Navarra A, Cicalini S, D’Arezzo S, et al. Vancomycin-resistant enterococci: screening efficacy and the risk of bloodstream infections in a specialized healthcare setting. Antibiotics (Basel). 2025;14(3):304. doi:10.3390/antibiotics14030304.
  14. Blagojevic C, Brown KA, Diong C, et al. Long-term risk of infection among patients colonized with antimicrobial-resistant pathogens: a population-wide cohort study. Open Forum Infect Dis. 2024;11(12):ofae712. doi:10.1093/ofid/ofae712.
  15. Alevizakos M, Gaitanidis A, Nasioudis D, Tori K, Flokas ME, Mylonakis E. Colonization with vancomycin-resistant enterococci and risk for bloodstream infection among patients with malignancy: a systematic review and meta-analysis. Open Forum Infect Dis. 2017;4(1):ofw246. doi:10.1093/ofid/ofw246.
  16. Rubin IMC, Pedersen MS, Mollerup S, et al. Association between vancomycin-resistant Enterococcus faecium colonization and subsequent infection: a retrospective WGS study. J Antimicrob Chemother. 2020;75(7):1712-1715. doi:10.1093/jac/dkaa074.
  17. Raad II, Hanna HA, Boktour M, et al. Catheter-related vancomycin-resistant Enterococcus faecium bacteremia: clinical and molecular epidemiology. Infect Control Hosp Epidemiol. 2005;26(7):658-661. doi:10.1086/502598.
  18. Zaas AK, Song X, Tucker P, Perl TM. Risk factors for development of vancomycin-resistant enterococcal bloodstream infection in patients with cancer who are colonized with vancomycin-resistant enterococci. Clin Infect Dis. 2002;35(10):1139-1146. doi:10.1086/342904.
  19. Barbosa D, Lima L, Silbert S, et al. Evaluation of the prevalence and risk factors for colonization by vancomycin-resistant Enterococcus among patients on dialysis. Am J Kidney Dis. 2004;44(2):337-343. doi:10.1053/j.ajkd.2004.04.038.
  20. Vergis EN, Hayden MK, Chow JW, et al. Determinants of vancomycin resistance and mortality rates in enterococcal bacteremia: a prospective multicenter study. Ann Intern Med. 2001;135(7):484-492. doi:10.7326/0003-4819-135-7-200110020-00007.
  21. Doganci M, Izdes S, Cirik MO. The evaluation of risk factors for vancomycin-resistant Enterococcus colonization and infection among mixed adult intensive care unit patients. Cureus. 2023;15(1):e33210. doi:10.7759/cureus.33210.
  22. Batistão DW, Gontijo-Filho PP, Conceição N, Oliveira AG, Ribas RM. Risk factors for vancomycin-resistant enterococci colonisation in critically ill patients. Mem Inst Oswaldo Cruz. 2012;107:57-63. doi:10.1590/S0074-02762012000100008.
  23. Byers KE, Anglim AM, Anneski CJ, Farr BM. Duration of colonization with vancomycin-resistant Enterococcus. Infect Control Hosp Epidemiol. 2002;23(4):207-211. doi:10.1086/502036.
  24. Humphreys H. Controlling the spread of vancomycin-resistant enterococci: is active screening worthwhile? J Hosp Infect. 2014;88(4):191-198. doi:10.1016/j.jhin.2014.09.002.
  25. Jung E, Byun S, Lee H, Moon SY, Lee H. Vancomycin-resistant Enterococcus colonization in the intensive care unit: clinical outcomes and attributable costs of hospitalization. Am J Infect Control. 2014;42(10):1062-1066. doi:10.1016/j.ajic.2014.06.024.
  26. Meschiari M, Kaleci S, Monte MD, et al. Vancomycin-resistant Enterococcus risk factors for hospital colonization in hematological patients: a matched case-control study. Antimicrob Resist Infect Control. 2023;12:126. doi:10.1186/s13756-023-01332-x.
  27. Paule SM, Trick WE, Tenover FC, et al. Comparison of PCR assay to culture for surveillance detection of vancomycin-resistant enterococci. J Clin Microbiol. 2003;41:4805-4807. doi:10.1128/JCM.41.10.4805-4807.2003.
  28. Muto CA, Giannetta ET, Durbin LJ, Simonton BM, Farr BM. Cost-effectiveness of perirectal surveillance cultures for controlling vancomycin-resistant Enterococcus. Infect Control Hosp Epidemiol. 2002;23(8):429-435. doi:10.1086/502080.